Cantor Fitzgerald started coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research note published on Wednesday morning, MarketBeat.com reports. The firm issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Palvella Therapeutics’ FY2024 earnings at ($3.02) EPS.
Palvella Therapeutics Stock Performance
NASDAQ:PVLA opened at $12.05 on Wednesday. Palvella Therapeutics has a one year low of $6.20 and a one year high of $22.32.
Insider Activity
In related news, Director George M. Jenkins purchased 4,000 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were bought at an average price of $12.93 per share, with a total value of $51,720.00. Following the acquisition, the director now owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This trade represents a 2.26 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Recommended Stories
- Five stocks we like better than Palvella Therapeutics
- What Does a Stock Split Mean?
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Dividend Capture Strategy: What You Need to Know
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- What is Put Option Volume?
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
